CONFERENCES

      International Conference on Bioinformatics and Biomedical Science

      ICBBS is an annual conference that focuses on the latest developments in bioinformatics and biomedical science, with topics ranging from data analysis to drug discovery. The conference is aimed at bioinformaticians, biomedical researchers, and other professionals involved in the study and application of bioinformatics and biomedical science, and provides a forum for sharing knowledge and collaborating on new approaches to research and discovery.

      6th ICBBS Conference 2017

      Date

      May 28, 2017 - May 29, 2017

      Location

      Chiba, Japan

      The ICBBS 2017 is organized by the Center for Bioinformatics and Computational Biology (CBBC) at the National University of Singapore (NUS) and provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Bioinformatics and Biomedical Science.

      See related presentations

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.